Pharmaceutical

Shionogi secures licence for Maze’s Pompe disease treatment

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.

May 11, 2024 - 04:00
Shionogi secures licence for Maze’s Pompe disease treatment
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001 aimed at treating Pompe disease.
Read the original article

Tags:

Previous Article

Oral solid dosage manufacturing companies, equipment and market

Next Article

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The high out-of-pocket cost of donating a kidney

Opinion: The high out-of-pocket cost of donating a kidney

Aug 5, 2023

UCB to divest China neurology and allergy business for $680m

UCB to divest China neurology and allergy business for ...

Aug 27, 2024

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux

Biotechs investigate ways to adapt to new clinical tria...

Sep 20, 2024